MarkNtel Advisors' industry professionals present a comprehensive and professional study of the Hypercholesterolemia Market.

With the massive size of the cholesterol-lowering drug market, these results beg the question: Could MK-0616 be the next hit ...

In fiscal year 2023, the managing heterozygous familial hypercholesterolemia (HEFH) management market is anticipated to be valued US$ 15.11 Billion, up from US$ 13.2 billion in fiscal year 2022. The ...

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today ...

Health screening and genetic tests might identify more than 1 million U.S. adults who carry a gene for familial hypercholesterolemia, a common genetic disorder that causes elevated low-density ...

Cholesterol concentrations in many patients with familial hypercholesterolemia are poorly controlled despite dietary changes and maximum pharmacologic therapy. Increased concentrations of ...

In a recent article published in the journal Nutrition, researchers in Australia summarized how diet could help decrease ...

Clin Lipidology. 2013;8(4):407-409. Homozygous familial hypercholesterolemia is a rare but significant cause of early-onset coronary heart disease. Early detection and diagnosis is crucial in at ...

How much should you eat? Experts weigh in. → Love Lemongrass? Get nutritional facts, tips from health experts, and more ...

Pharmacodynamics of the immune response will be measured by LDL cholesterol levels, an established model of PCSK9 inhibition in hypercholesterolemia. "We're excited to get this first-in-human ...